{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:17:55Z","timestamp":1793755075553,"version":"4.6.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03555-2","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:26:28Z","timestamp":1744860388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nocturnal baricitinib administration leads to rapid drug responses in rheumatoid arthritis: a multicenter non-randomized controlled study"],"prefix":"10.1186","volume":"27","author":[{"given":"Teppei","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuteru","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Sibanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hashiramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"3555_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Nat Rev Dis Primers"},{"key":"3555_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrrheum.2017.115","volume":"13","author":"C Orr","year":"2017","unstructured":"Orr C, Vieira-Sousa E, Boyle DL, Buch MH, Buckley CD, Ca\u00f1ete JD, et al. Synovial tissue research: a state-of-the-art review. Nat Rev Rheumatol. 2017;13:463\u201375.","journal-title":"Nat Rev Rheumatol"},{"key":"3555_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"3555_CR4","doi-asserted-by":"publisher","first-page":"e170998","DOI":"10.1172\/JCI170998","volume":"134","author":"LA Schrader","year":"2024","unstructured":"Schrader LA, Ronnekleiv-Kelly SM, Hogenesch JB, Bradfield CA, Malecki KM. Circadian disruption, clock genes, and metabolic health. J Clin Invest. 2024;134:e170998.","journal-title":"J Clin Invest"},{"key":"3555_CR5","first-page":"940","volume":"20","author":"NJ Olsen","year":"1993","unstructured":"Olsen NJ, Brooks RH, Furst D. Variability of Immunologic and clinical features in patients with rheumatoid arthritis studied over 24 hours. J Rheumatol. 1993;20:940\u20133.","journal-title":"J Rheumatol"},{"key":"3555_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/art.22368","volume":"56","author":"RH Straub","year":"2007","unstructured":"Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007;56:399\u2013408.","journal-title":"Arthritis Rheum"},{"key":"3555_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jbspin.2018.09.003","volume":"86","author":"M Cutolo","year":"2019","unstructured":"Cutolo M. Circadian rhythms and rheumatoid arthritis. Joint Bone Spine. 2019;86:327\u201333.","journal-title":"Joint Bone Spine"},{"key":"3555_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/ard.23.2.158","volume":"23","author":"JR De Andrade","year":"1964","unstructured":"De Andrade JR, McCormick JN, Hill AG. Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis. 1964;23:158\u201362.","journal-title":"Ann Rheum Dis"},{"key":"3555_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1136\/ard.43.6.790","volume":"43","author":"M De Silva","year":"1984","unstructured":"De Silva M, Binder A, Hazleman BL. The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis. Ann Rheum Dis. 1984;43:790\u201393.","journal-title":"Ann Rheum Dis"},{"key":"3555_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/ard.56.1.27","volume":"56","author":"NG Arvidson","year":"1997","unstructured":"Arvidson NG, Gudbj\u00f6rnsson B, Larsson A, H\u00e4llgren R. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis. 1997;56:27\u201331.","journal-title":"Ann Rheum Dis"},{"key":"3555_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(08)60132-4","volume":"371","author":"F Buttgereit","year":"2008","unstructured":"Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371:205\u201314.","journal-title":"Lancet"},{"key":"3555_CR12","doi-asserted-by":"publisher","first-page":"106549","DOI":"10.1016\/j.intimp.2020.106549","volume":"84","author":"A Yaekura","year":"2020","unstructured":"Yaekura A, Yoshida K, Morii K, Oketani Y, Okumura I, Kaneshiro K, et al. Chronotherapy targeting cytokine secretion attenuates collagen-induced arthritis in mice. Int Immunopharmacol. 2020;84:106549.","journal-title":"Int Immunopharmacol"},{"key":"3555_CR13","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1096\/fj.201600353R","volume":"30","author":"LE Hand","year":"2016","unstructured":"Hand LE, Hopwood TW, Dickson SH, Walker AL, Loudon AS, Ray DW, et al. The circadian clock regulates inflammatory arthritis. FASEB J. 2016;30:3759\u201370.","journal-title":"FASEB J"},{"key":"3555_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1254\/jphs.11029FP","volume":"116","author":"K Okabayashi","year":"2011","unstructured":"Okabayashi K, Tomonari M, Yoshimatsu H, Fukuyama R, Ieiri I, Higuchi S, et al. Dosing time-dependency of the arthritis-inhibiting effect of tacrolimus in mice. J Pharmacol Sci. 2011;116:264\u201373.","journal-title":"J Pharmacol Sci"},{"key":"3555_CR15","unstructured":"European medicines agency. Summary of product characteristics, Olumiant (Baricitinib) film-coated tablets: EU summary of product characteristics. 2017. Available online: http:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf"},{"key":"3555_CR16","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American college of rheumatology\/european league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"3555_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727\u201335.","journal-title":"Arthritis Rheum"},{"key":"3555_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.42347","volume":"75","author":"P Studenic","year":"2023","unstructured":"Studenic P, Aletaha D, de Wit M, Stamm TA, Alasti F, Lacaille D, et al. American college of rheumatology\/eular remission criteria for rheumatoid arthritis: 2022 revision. Arthritis Rheumatol. 2023;75:15\u201322.","journal-title":"Arthritis Rheumatol"},{"key":"3555_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2021","unstructured":"Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2021;15:14\u201320.","journal-title":"Clin Kidney J"},{"key":"3555_CR20","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083\u2013107.","journal-title":"Stat Med"},{"key":"3555_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3\u201315.","journal-title":"Ann Rheum Dis"},{"key":"3555_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/annrheumdis-2011-201067","volume":"72","author":"F Buttgereit","year":"2013","unstructured":"Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013;72:204\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3555_CR23","doi-asserted-by":"publisher","first-page":"e000203","DOI":"10.1136\/rmdopen-2015-000203","volume":"2","author":"M Cutolo","year":"2016","unstructured":"Cutolo M. Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD Open. 2016;2(1):e000203.","journal-title":"RMD Open"},{"key":"3555_CR24","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652\u201362.","journal-title":"N Engl J Med"},{"key":"3555_CR25","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2016-209821","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 2017;76:694\u2013700.","journal-title":"Ann Rheum Dis"},{"key":"3555_CR26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/mr\/roac089","volume":"33","author":"M Takagi","year":"2023","unstructured":"Takagi M, Atsumi T, Matsuno H, Tamura N, Fujii T, Okamoto N, et al. Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. Mod Rheumatol. 2023;33:647\u201356.","journal-title":"Mod Rheumatol"},{"key":"3555_CR27","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/acr.23769","volume":"71","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Xie F, Yang S, Bernatsky S, Chen L, Yun H, et al. Risk for herpes Zoster in Tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids. Arthritis Care Res (Hoboken). 2019;71:1249\u201354.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03555-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03555-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03555-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:26:29Z","timestamp":1744860389000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03555-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3555"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03555-2","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Ethics Committees of Hyogo Medical University, Kobe City Medical Center West Hospital, Konan (Hakuhoukai), Kakogawa Hospital, and Kobe Kaisei Hospital. All participants signed informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AH: Honoraria from AbbVie G.K., and honoraria and grants from Eli Lilly Japan K.K., Asahikasei Pharma Co. and Chugai Pharmaceutical Co. TY (Takashi Yamane): Honoraria from GlaxoSmithKline K.K. KM: Grants from Asahikasei Pharma Co. and Chugai Pharmaceutical Co. The other authors: No conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}